Full-Time

Director – Combination Product Development

Confirmed live in the last 24 hours

Viatris

Viatris

10,001+ employees

No salary listed

Senior, Expert

Dublin, Ireland

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • The ideal candidate will be a qualified, highly experienced pharmaceutical professional with a proven track record of success, a positive attitude and who wants to progress in a fast-paced environment.
  • Experienced People Manager.
  • Masters/Degree in Engineering/Science with experience in R&D or Technical Support environment.
  • Previous experience of managing a technical team in an R&D environment.
  • Experienced in writing regulatory submissions.
  • Experienced in leading a technical team in support of FDA, HPRA or notified body inspections.
  • A working knowledge of ISO 13485 & FDA 21 CFR Part 820 Design Control requirements would be an advantage.
  • It is essential that the candidate will be both highly innovative and well organized, having excellent planning and communication skills and able to operate across all site teams.
  • In addition, the candidate must be able to work under pressure and have a proven track record of problem solving and effective time management.
  • Well-developed communication skills to lead or facilitate effective discussions. Able to communicate technical information to key stakeholders.
  • Some travel will be required as part of this role.
Responsibilities
  • People manager of Scientists and Engineers who support device development for Injectables, Respiratory and Transdermal combination products.
  • Build and expand team with responsibility for hiring new positions to support new technologies and programs within the Injectables, Respiratory and Transdermal portfolio.
  • Lead a team who support device development by generating the critical evidence that demonstrates to regulatory agencies that the combination product is safe, effective, reliable and fulfills regulatory requirements.
  • Responsible for technical interface between drug product and device teams during combination product development on elements such as primary container interface and compatibility, exhibit batch manufacture and stability studies.
  • Lead and provide technical oversight to a team responsible for design verification, stability, biological evaluation, extractables, and transport & shipping studies.
  • Responsible for leading a technical team during regulatory and notified body inspections by representing the team in front of auditors and ensuring audit readiness.
  • Overall responsible for method development, approval of method validations and test protocols and reports.
  • Technical oversight of team responsible for the development of design requirements and combination product specifications based on characterization of comparator products, regulatory requirements, design intent and user requirements.
  • Provide technical support to manufacturing sites during filling and assembly process development. Responsible for designing experiments and manufacturing trials to identify process controls, reliability requirements, sampling plans and release specifications.
  • Responsible for ensuring a device control strategy is in place to support combination product manufacture and transfer to manufacturing site.
  • Trending and statistical analysis of design verification and manufacturing data including compilation of technical reports to support combination product development lifecycle.
  • Ensures all activities within team are conducted and executed to the appropriate quality standards within the GDD Quality Management System.
Desired Qualifications
  • A working knowledge of ISO 13485 & FDA 21 CFR Part 820 Design Control requirements would be an advantage.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • DOJ's clearance of Mylan improves Viatris' public image and reduces legal uncertainties.
  • Consistent dividend policy for five years reflects Viatris' financial stability.
  • Participation in major healthcare conferences boosts Viatris' investor engagement.

What critics are saying

  • Increased competition from biosimilars threatens Viatris' market share.
  • Expiration of key drug patents in 2025 may lead to revenue loss.
  • Reliance on international markets exposes Viatris to geopolitical risks.

What makes Viatris unique

  • Viatris bridges the gap between generics and branded drugs globally.
  • Exclusive licensing with Lexicon enhances Viatris' cardiovascular portfolio outside U.S. and Europe.
  • Viatris' commitment to innovation is evident in its cenerimod research for lupus treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 27th, 2025
Viatris Maintains Dividend Policy For 2025 And Announces Quarterly Dividend

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 3rd, 2025
Viatris To Report Fourth Quarter And Full Year 2024 Financial Results On February 27, 2025

PITTSBURGH, Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc

PR Newswire
Oct 16th, 2024
Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals For Sotagliflozin In All Markets Outside Of The U.S. And Europe

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases. Leverages Viatris' Unique Global Infrastructure and Expertise. Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe